Canada: Court Determines Beneficial Ownership Of Several Patents As Part Of Action For Wrongful Conduct (Intellectual Property Weekly Abstracts Bulletin: Week Of October 13, 2014)

Last Updated: October 16 2014

Edited by Chantal Saunders and Beverley Moore , Adrian Howard and Ryan Steeves


Court Determines Beneficial Ownership of Several Patents as Part of Action for Wrongful Conduct

Nature-Control Technologies Inc. v. Li, 2014 BCSC 1868

This was an action by the Plaintiff for relief arising from the allegedly wrongful conduct of the Defendant Li. The Plaintiff claimed that Li breached the fiduciary duties he owed to it by diverting a business opportunity to one of the co-defendants, a company owned indirectly by Li and his wife (the "Li Company"). One of the issues to be decided in this case was the scope of the Plaintiff's business and, in particular, whether it included the sale of certain products. The Defendants argue that Li agreed to give the Plaintiff certain rights for certain compounds (the "Compounds"), but not for his "specialty bleaching and brightening products" (the "Products"). The Plaintiff maintains that the Compounds and Products were developed by Li at the Plaintiff's laboratory and at its cost. The costs of registering the patents in respect of the Compounds and Products were originally borne by the Li Company, but it was agreed that the Plaintiff would reimburse the Li Company. Therefore, the Court was asked to determine, among other things, whether the Plaintiff beneficially owns the intellectual property (patents and trademarks) in the name of the Li Company.

Following a review of the scope of the Plaintiff's business, the Court determined that two (2) patents and four (4) trademarks are beneficially owned by the Li Company. With respect to the patents covering the Compounds, the Court held that there is a presumption that an inventor, even one who is an employee, is entitled to the benefit of his own invention. However, two exceptions exist: (1) where there is an express contract to the contrary; or (2) where the person was employed for the express purpose of inventing or innovating. Based on the evidence in this regard, the Court held that Li retained the beneficial ownership of the Compound patents. With respect to a "FAS Patent", the Plaintiff was held to be the beneficial owner. The Court held that the parties impliedly intended for the Plaintiff to own the FAS Patent, as it asked Li to "come up with a solution" to address an "opportunity". In addition, the Court found that the conduct of the parties supported this conclusion, as well as the fact that the Plaintiff paid the costs associated with registering the patent. Li was therefore ordered to assign the FAS Patent to the Plaintiff.

Patent Not Eligible for Listing: Patent Claiming One Medicinal Ingredient, but directed to a Fixed-Dose Combination of Medicines

ViiV Healthcare ULC v. Teva Canada Limited, 2014 FC 893

This was an appeal from two decisions for three proceedings before Prothonotary Milczynski, in which she determined that a patent could not be listed on the Patent Register under the PM(NOC) Regulations (the "Regulations"). The issue to be decided on appeal, according to Justice Hughes, is "arcane": "can a patent claiming but one medicinal ingredient be listed by the Minister of Health under the Regulations where the underlying Notice of Compliance ("NOC") is directed to a fixed-dose combination ("FDC") of two or more medicines?"

The Applicant (ViiV Healthcare) and the Minister of Health (the "Minister") are common in all three proceedings, while Teva is the Respondent in one (see 2014 FC 328), and Apotex is the Respondent in the others (see 2014 FC 893). The Prothonotary gave the same Order in the Apotex proceedings as she did in the Teva proceeding. These proceedings concern two of the Applicant's drugs: KIVEXA®, a FDC tablet containing two active ingredients and TRIZIVIR®, another FDC tablet containing three active ingredients. The Applicant's Canadian Patent No. 2,289,753 (the " '753 Patent") was listed on the Register in respect of each of KIVEXA® and TRIZIVIR®.

Prothonotary Milczynski determined that the '753 Patent was not eligible for listing against KIVEXA® or TRIZIVIR®. The Prothonotary based her decision on the product specificity requirements listed at paragraphs 4(2)(a) and (b) of the Regulations (Re: claim for the medicinal ingredient and the formulation, respectively), as well as the decision of the Federal Court of Appeal in Gilead Sciences (see 2012 FCA 254). The Court undertook an extensive review of the current jurisprudence dealing with the propriety of the listing of certain patents under the Regulations as amended in 2006 (see para. 47). Based on the jurisprudence, the Court made the following notable conclusions: (i) absent precise and specific matching between what the patent claims and the product/use/dosage forms for which the NOC has been granted to the first person, the Minister cannot properly list the patent; (ii) a claim for a formulation includes both medicinal and non-medicinal ingredients, while a claim directed to medicinal ingredients, without claims also to non-medicinal ingredients, does not qualify for listing as a formulation; and (iii) where a patent claims only one medicinal ingredient, it cannot be listed as against an NOC obtained for two (or more) medicinal ingredients. The Court rejected a number of policy arguments advanced by the Applicant in favour of listing patents containing FDCs. In addition, the Court addressed the issue of whether FDCs are unique so as to be able to be listed under the Regulations. It concluded in the negative, holding that "every medicine in the envelope [by way of analogy] must be claimed". The Court also noted that, in this case, the evidence was ambiguous as to whether there were separate medicines functioning independently, or whether they interacted and were synergistic. However, the Court found this type of analysis useless: "[a] patent claim for only one medicinal ingredient cannot support a listing under the NOC Regulations where the underlying NOC is for a combination (synergistic or otherwise) of two or more medicinal ingredients."

Therefore, the Court upheld the Orders of Prothonotary Milczynski holding that the '753 Patent was ineligible for listing on the Register. The Applicant's motions, by way of this appeal, were dismissed. The Court stayed its Orders in respect of the Apotex proceedings (to permit the Applicant to file an appeal, if so advised) since the orders effectively terminated those proceedings. Costs were awarded to Teva and Apotex, although Apotex was awarded half the amount since its appeals largely followed Teva's.


Trademark NIC OUT Ordered Struck from Registry in Expungement Proceeding

TLG Canada Corp. v. Product Source International LLC, 2014 FC 924

This was an expungement proceeding for an order striking the registration for NIC OUT, a trademark for cigarette filters that remove tar and nicotine, held by the Respondent, Product Source International LLC ("Product Source"). Product Source brought an infringement action against the Applicant ("TLG Canada") for selling "NIC-OUT" cigarette filters. TLG Canada argued that its Nic-Out product was distributed and sold in Canada as early as 2001, whereas Product Source (NIC OUT) alleged that it started using its product in 2003 (Registration of the NIC OUT mark was in 2008).

The Court held that the registration for NIC OUT should be struck from the Registry because it is invalid under section 18(1)(a) because it was not registrable on the date it was registered. It was found that it was confusing to the Nic-Out trademark and Product Source knew at the time of the application that: (1) the confusing mark NIC-OUT was previously used in Canada, and (2) the trademark NIC OUT was not distinctive. Therefore, Product Source's trademark NIC OUT was expunged from the Registry, and costs were awarded to TLG Canada in the amount of $10,000.


CIPO has released a new document titled the "Search Report", which outlines the search and examination work that is conducted by the Patent Branch examiners during national patent examinations.The document is provided for reference only, and will be annexed to examination reports.

CIPO has announced that it will be holding an official consultation on the report entitled Modernizing the IP Community (the "Report") from October 9, 2014 to December 9, 2014. CIPO is seeking views to assess the degree to which the recommendations contained in the Report meet the needs of the business community and the IP professional community. A summary overview of CIPO's initiative can be found here.

Recent reports have suggested that the government will be seeking to amend the Copyright Act (through the Budget Implementation Act) to provide an exception to copyright infringement for political advertising. According to news reports, the proposed exception will allow free use of "news" content in political advertisements in specific situations, and only by political officials or their agents. The issue was debated briefly in the House of Commons on October 10, 2014, amid the reports.

CIPO has also announced that it is in the process of revising and modernizing the Manual of Patent Office Practice (MOPOP). As of October 1, 2014, minor updates have been made to Chapters 8 and 19.

A minor amendment to the Industrial Design Regulations has been made, repealing subsection 12(3) relating to the electronic filing of documents. In 2009, the Standing Joint Committee for the Scrutiny of Regulations found that the subsection was invalid due to an inconsistency between the English and French versions of the Industrial Design Act. CIPO took the position that it could not, at the moment, amend the Act to correct this one inconsistency. Therefore, the subsection was simply repealed since it was decided that its removal would have no impact on the effectiveness of the Regulations.

The BLG Life Sciences Group has published LIFESIGNS: Life Sciences Legal Trends in Canada, a Report on Intellectual Property, Litigation, Corporate Commercial legal trends and industry developments in Canada.

About BLG

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions